Acquired amegakaryocytic thrombocytopenic purpura induced by percutaneous ethanol injection during treatment of hepatocellular carcinoma: A case report

Ai,Ding‑Lun; Li,Bo‑Tao; Peng,Xiao‑Ming; Zhang,Lin‑Zhi; Wang,Jing‑Yan; Zhao,Yun; Yang,Bin; Yu,Qiang; Liu,Chun‑Zi; Yang,Ning; Wang,Hua‑Ming; Zhou,Lin

doi:10.3892/ol.2015.3934

Acquired amegakaryocytic thrombocytopenic purpura induced by percutaneous ethanol injection during treatment of hepatocellular carcinoma: A case report

Authors:
- Ding‑Lun Ai
- Bo‑Tao Li
- Xiao‑Ming Peng
- Lin‑Zhi Zhang
- Jing‑Yan Wang
- Yun Zhao
- Bin Yang
- Qiang Yu
- Chun‑Zi Liu
- Ning Yang
- Hua‑Ming Wang
- Lin Zhou
View Affiliations

Affiliations: Department of Interventional Radiology, Beijing 302nd Hospital, Beijing 100039, P.R. China, Department of Hematopoietic Stem Cell Transplantation, Affiliated Hospital to the Chinese Academy of Military Medical Sciences, Beijing 100071, P.R. China, Department of Clinical Laboratory, Beijing 302nd Hospital, Beijing 100039, P.R. China
Published online on: November 17, 2015 https://doi.org/10.3892/ol.2015.3934
Pages: 798-800

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Percutaneous ethanol injection is an important localized treatment method for patients presenting with hepatocellular carcinoma (HCC). Among the advantages of percutaneous ethanol injection are its minimal invasiveness, simplicity, low cost and low risk of complications. However, the increasing popularity of percutaneous ethanol injection has resulted in serious adverse effects attributed to individual variations. The present study describes the case of a patient who exhibited acquired amegakaryocytic thrombocytopenic purpura, caused by percutaneous ethanol injection treatment for HCC. This complication was promptly identified, and platelet transfusion and injection of recombinant human interleukin‑11 resulted in a rapid recovery of the patient's platelet count. Attention should be given to this rare complication in patients administered percutaneous ethanol injection treatment for HCC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Said A and Wells J: Management of hepatocellular carcinoma. Minerva Med. 100:51–68. 2009.PubMed/NCBI
3	Livraghi T, Benedini V, Lazzaroni S, Meloni F, Torzilli G and Vettori C: Long term results of single session percutaneous ethanol injection in patients with large hepatocellular carcinoma. Cancer. 83:48–57. 1998. View Article : Google Scholar : PubMed/NCBI
4	Shiina S, Tateishi R, Imamura M, Teratani T, Koike Y, Sato S, Obi S, Kanai F, Kato N, Yoshida H, et al: Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors. Liver Int. 32:1434–1442. 2012. View Article : Google Scholar : PubMed/NCBI
5	Weis S, Franke A, Berg T, Mössner J, Fleig WE and Schoppmeyer K: Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database Syst Rev. 1:CD0067452015.PubMed/NCBI
6	Ebara M, Kita K, Yoshikawa M and Ohto M: Non-vascular interventional radiology - percutaneous ethanol injection (PEI) in hepatocellular carcinoma smaller than 3 cm in diameter. Gan To Kagaku Ryoho. 16:3311–3318. 1989.(In Japanese). PubMed/NCBI
7	Morimoto M, Numata K, Sugimori K, Shirato K, Kokawa A, Oka H, Hirasawa K, Koh R, Nihommatsu H and Tanaka K: Successful initial ablation therapy contributes to survival in patients with hepatocellular carcinoma. World J Gastroenterol. 13:1003–1009. 2007. View Article : Google Scholar : PubMed/NCBI
8	Castroagudín JF, Delgado M, Villanueva A, Bustamante M, Martínez J, Otero E, Tomé S, Martínez SM, Segade FR, Conde R, et al: Safety of percutaneous ethanol injection as neoadjuvant therapy for hepatocellular carcinoma in waiting list liver transplant candidates. Transplant Proc. 37:3871–3873. 2005. View Article : Google Scholar : PubMed/NCBI
9	Livraghi T, Giorgio A, Marin G, Salmi A, de Sio I, Bolondi L, Pompili M, Brunello F, Lazzaroni S and Torzilli G: Hepatocellular carcinoma and cirrhosis in 746 patients: Long-term results of percutaneous ethanol injection. Radiology. 197:101–108. 1995. View Article : Google Scholar : PubMed/NCBI
10	Gelczer RK, Charboneau JW, Hussain S and Brown DL: Complications of percutaneous ethanol ablation. J Ultrasound Med. 17:531–533. 1998.PubMed/NCBI
11	Lai DW, Loughran TP Jr, Maciejewski JP, Sasu S, Song SX, Epling-Burnette PK and Paquette RL: Acquired amegakaryocytic thrombocytopenia and pure red cell aplasia associated with an occult large granular lymphocyte leukemia. Leuk Res. 32:823–827. 2008. View Article : Google Scholar : PubMed/NCBI
12	Quintás-Cardama A: Acquired amegakaryocytic thrombocytopenic purpura successfully treated with limited cyclosporin A therapy. Eur J Haematol. 69:185–186. 2002. View Article : Google Scholar : PubMed/NCBI
13	Tristano AG: Acquired amegakaryocytic thrombocytopenic purpura: Review of a not very well-defined disorder. Eur J Intern Med. 16:477–481. 2005. View Article : Google Scholar : PubMed/NCBI
14	Hirsh EH, Vogler WR, McDonald TP and Stein SF: Acquired hypomegakaryocytic thrombocytopenic purpura. Occurrence in a patient with absent thrombopoietic stimulating factor. Arch Intern Med. 140:721–723. 1980. View Article : Google Scholar : PubMed/NCBI
15	Gewirtz AM and Hoffman R: Transitory hypomegakaryocytic thrombocytopenia: Aetiological association with ethanol abuse and implications regarding regulation of human megakaryocytopoiesis. Br J Haematol. 62:333–344. 1986. View Article : Google Scholar : PubMed/NCBI
16	Kaushansky K, Lichtman MA, Beutler E, Kipps TJ, Seligsohn U and Prchal J: Williams Hematology (8th). New York, NY: McGraw-Hill. 2010.PubMed/NCBI
17	Latvala J, Parkkila S and Niemelä O: Excess alcohol consumption is common in patients with cytopenia: Studies in blood and bone marrow cells. Alcohol Clin Exp Res. 28:619–624. 2004. View Article : Google Scholar : PubMed/NCBI
18	Tristano AG: Acquired amegakaryocytic thrombocytopenic purpura: Review of a not very well-defined disorder. Eur J Int Med. 16:477–481. 2005. View Article : Google Scholar
19	Smith CM 2nd, Tobin JD Jr, Burris SM and White JG: Alcohol consumption in the guinea pig is associated with reduced megakaryocyte deformability and platelet size. J Lab Clin Med. 120:699–706. 1992.PubMed/NCBI
20	Kantarjian H, Giles F, List A, Lyons R, Sekeres MA, Pierce S, Deuson R and Leveque J: The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer. 109:1705–1714. 2007. View Article : Google Scholar : PubMed/NCBI
21	Weich NS, Wang A, Fitzgerald M, Neben TY, Donaldson D, Giannotti J, Yetz-Aldape J, Leven RM and Turner KJ: Recombinant human interleukin-11 directly promotes megakaryocytopoiesis in vitro. Blood. 90:3893–3902. 1997.PubMed/NCBI
22	Cantor SB, Elting LS, Hudson DV Jr and Rubenstein EB: Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy. Cancer. 97:3099–3106. 2003. View Article : Google Scholar : PubMed/NCBI